EHVA fosters a multidisciplinary approach to the challenge of developing broadly effective HIV vaccines.

EHVA’s programme primary goals are to:

  • To develop a Multidisciplinary Vaccine Platform (MVP) for prophylactic and therapeutic HIV vaccines
  • To move at least two novel prophylactic vaccine candidates to clinical development
  • To identify immune correlates associated with control of HIV replication following immunological intervention
  • To establish astrong scientific basis for further development of EHVA vaccine candidates in larger clinical trials

News

  • EHVA P01: a phase I, prophylactic HIV vaccine trial

    EHVA P01 / ANRS VRI08 is a phase I, prophylactic HIV vaccine trial to evaluate the safety and...

    Read More …

  • EHVA Latest News

    EHVA latest newsletter is available...

    Read More …

  • EHVA Halts Phase II EHVA-T02 Clinical Trial of a Candidate Therapeutic HIV Vaccine and Immunotherapy Drug

    The European HIV Vaccine Alliance (EHVA) has announced that the EHVA T02 / ANRS VRI07 trial, a...

    Read More …

europa  

This project has received funding from the European Union's Horizon 2020 research
and innovation programme under grant agreement N° 681032